Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709768 | 0.81 | CES1 (0.43) | CES1CES2MAPK14RAB9AALDH1A1 | |
| SCHEMBL14609753 | 0.77 | HDAC3 (0.45) | HDAC3HDAC1HDAC2 | |
| SCHEMBL10020220 | 0.77 | CES1 (0.52) | CES1CES2RAB9AALDH1A1HPGD | |
| SCHEMBL5771051 | 0.73 | CES1 (0.47) | CES1CES2MAPK14ALDH1A1HPGD | |
| SCHEMBL7205226 | 0.73 | CES1 (0.47) | CES1CES2MAPK13MAPK12MAPK11 | |
| SCHEMBL709297 | 0.67 | GRM5 (0.42) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7206668 | 0.67 | MAPT (0.44) | CES1CES2MAPK14RAB9AALDH1A1 | |
| SCHEMBL1554486 | 0.66 | MAPK14 (0.36) | MAPK14RAB9AALDH1A1USP2CYP1A2 | |
| SCHEMBL25876463 | 0.66 | MAPT (0.58) | MAPK14HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL716295 | 0.66 | CES2 (1.00) | CES1CES2RAB9ANPC1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | CES1 2934/4885CES2 1662/4885MAPK13 1862/4885 |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | CES1 2934/4885CES2 1662/4885MAPK13 1862/4885 |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | CES1 2934/4885CES2 1662/4885MAPK13 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.